Iron deficiency and heart failure
Iron is a micronutrient essential for cellular energy and metabolism, necessary for maintaining body homoeostasis. Iron deficiency (ID) is an important co-morbidity in patients with heart failure (HF). A major factor in the pathogenesis of anaemia, it is also a separate condition with serious clinic...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | |
| Formato: | Capítulo de libro |
| Lenguaje: | Español |
| Publicado: |
Silver Horse SRL
2016
|
| Acceso en línea: | Registro en Scopus Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 38475caa a22022457a 4500 | ||
|---|---|---|---|
| 001 | PAPER-24574 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205627.0 | ||
| 008 | 190411s2016 xx ||||fo|||| 00| 0 spa|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-84978661449 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 100 | 1 | |a Perel, C. | |
| 245 | 1 | 0 | |a Iron deficiency and heart failure |
| 246 | 3 | 1 | |a Deficiência de ferro e insuficiência cardíaca |
| 246 | 3 | 1 | |a Deficiencia de hierro e insuficiencia cardíaca |
| 260 | |b Silver Horse SRL |c 2016 | ||
| 270 | 1 | 0 | |m Bevacqua, R.J.; División Cardiología, Pabellón Inchauspe, Hospital General de Agudos "Dr. J. M. Ramos Mejía", GCBAArgentina; email: raulbev@hotmail.com |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a de Silva, R., Rigby, A.S., Witte, K.K., Nikitin, N.P., Tin, L., Goode, K., Bhandari, S., Cleland, J.G., Anemia, renal dysfunction, and their interaction in patients with chronic heart failure (2006) Am J Cardiol, 98, pp. 391-398 | ||
| 504 | |a Clark, A.L., Poole-Wilson, P.A., Coats, A.J., Exercise limitation in chronic heart failure: Central role of the periphery (1996) J Am Coll Cardiol, 28, pp. 1092-1102 | ||
| 504 | |a Westenbrink, B.D., Visser, F.W., Voors, A.A., Smilde, T.D., Lipsic, E., Navis, G., Hillege, H.L., van Veldhuisen, D.J., Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well (2007) Eur Heart J, 28, pp. 166-171 | ||
| 504 | |a Opasich, C., Cazzola, M., Scelsi, L., De, F.S., Bosimini, E., Lagioia, R., Febo, O., Tavazzi, L., Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure (2005) Eur Heart J, 26, pp. 2232-2237 | ||
| 504 | |a Andrews, N.C., Bridge, K.R., (1998) Disorders of iron metabolism and sideroblastic anemia. Nathan and Oski’s Hematology of infancy and childhood, pp. 423-461. , 5th ed. Philadelphia: WB Saunders | ||
| 504 | |a Hentze, M.W., Iron regulatory factor-the conductor of cellular iron regulation. 27th Annual Course (1993) Advan Haematol, pp. 36-48 | ||
| 504 | |a Anker, S., von Haehling, S., (2009) Anaemia in Chronic Heart Failure, , 1st ed. Bremen: International Medical Publishers | ||
| 504 | |a Lanzkowski, P., Metabolismo del hierro y anemia ferripriva (1985) Hematología pediátrica, pp. 121-193. , 3a ed. La Habana, Edición Revolucionaria | ||
| 504 | |a Refsun, A.B., Schreiner, B.B.I., Regulation of iron balance by absorption and excretion (1984) Scand J Gastroenterol, 19, pp. 867-874 | ||
| 504 | |a Wick, M., Pinggera, W., Lehmann, P., (1996) Iron metabolism, diagnosis and therapy of anemias, , 3th ed. New York: Springer | ||
| 504 | |a Fairbanks, V., Klee, G., (1986) Biochemical aspects of hematology. En: Textbook of clinical chemistry, , Tietz. Philadelphia: WB Saunders | ||
| 504 | |a Maeyer, E., (1989) Preventing and controlling iron deficiency anemia through primary health care, , Geneva, World Health Organization | ||
| 504 | |a Guix, P., Parera, M., Castro, J.A., Picornell, A., Ramón, M.M., Obrador, A., Aspectos moleculares de la absorción duodenal de hierro (2003) Gastroenterol Hepatol, 26 (2), pp. 86-93 | ||
| 504 | |a McKie, A.T., Barrow, D., Latunde-Dada, G.O., Rolfs, A., Sager, G., Mudaly, E., An iron regulated ferric reductase associated with the absorption of dietary iron (2001) Science, 291, pp. 1755-1759 | ||
| 504 | |a Sharma, D.C., Mathur, R., Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid (1995) Indian J Physiol Pharmacol, 39, pp. 403-406 | ||
| 504 | |a Roy, C.N., Enns, C.A., Iron homeostasis: New tales from the crypt (2000) Blood, 96, pp. 4020-4027 | ||
| 504 | |a Conrad, M.E., Crosby, W.H., Intestinal mucosal mechanism controlling iron absorption (1963) Blood, 22, pp. 406-415 | ||
| 504 | |a Gunshin, H., Mackenzie, B., Berger, U.V., Gunshin, Y., Romero, M.F., Boron, W.F., Cloning and characterization of a mammalian proton-coupled metal-ion transporter (1997) Nature, 388, pp. 482-488 | ||
| 504 | |a Andrews, N.C., The iron transporter DMT1 (1999) Int J Biochem Cell Biol, 31, pp. 991-994 | ||
| 504 | |a Anderson, G.J., Control of iron absorption (1996) J Gastroenterol Hepatol, 11, pp. 1030-1032 | ||
| 504 | |a Conrad, M.E., Umbreit, J.N., Iron absorption-mucinmobilferrinintegrin pathway. A competitive pathway for metal absorption (1993) Am J Hematol, 42, pp. 67-73 | ||
| 504 | |a Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S.J., Moynihan, J., Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter (2000) Nature, 403, pp. 776-781 | ||
| 504 | |a McKie, A.T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., A novel duodenal ion-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation (2000) Mol Cell, 5, pp. 299-309 | ||
| 504 | |a Abboud, S., Haile, D.J., A novel mammalian iron regulated protein involved in intracellular iron metabolism (2000) J Biol Chem, 275, pp. 19906-19912 | ||
| 504 | |a Vulpe, C.D., Kuo, Y.M., Murphy, T.L., Cowley, L., Askwith, C., Libina, N., Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse (1999) Nat Genet, 21, pp. 195-199 | ||
| 504 | |a Huebers, H.A., Finch, C.A., The physiology of transferrin and transferrin receptor (1987) Physiol Rev, 67, pp. 520-526 | ||
| 504 | |a Haupt, H., Baudner, S., Chemie und Klinische bedentung der human. Plasma Proteine (1990) Behring Institut Mitteilungen, 86, pp. 1-66 | ||
| 504 | |a Lee, G.R., Herbert, V., Nutritional factors in the production and function of erythrocytes (1998) Wintrobe’s Clinical Hematology, pp. 228-266. , 10th ed. Baltimore: William and Wilkins | ||
| 504 | |a Finch, C., Huebers, H., Eng, M., Miller, L., Effect of transfused reticulocytes on iron exchange (1982) Blood, 59, pp. 364-369 | ||
| 504 | |a Gimferrer, E., Ubeda, J., Royo, M.T., El Receptor de la transferrina (1996) Bioferrum, 1, pp. 49-50 | ||
| 504 | |a Pomka, P., Cellular iron metabolism (1999) Kidney Int, 55, pp. 2-11 | ||
| 504 | |a Worwood, M., Regulación del metabolismo del hierro (1995) An Nestlé, 53, pp. 1-11 | ||
| 504 | |a Cook, J.D., Skikne, B.S., Baynes, R.D., Serum transferrin receptor (1993) Annu Rev Med, 44, pp. 63-74 | ||
| 504 | |a Thorstensen, K., Romslo, Y., The transferrin receptor its diagnostic value and its potential as therapeutic target (1993) Scand Clin Lab Invest, 53, pp. 113-120 | ||
| 504 | |a Andrews, N.C., Disorders of iron metabolism (1999) N Engl J Med, 341, pp. 1986-1995 | ||
| 504 | |a Weiss, G., Goodnough, L.T., Anemia of chronic disease (2005) N Engl J Med, 352, pp. 1011-1023 | ||
| 504 | |a Handelman, G.J., Levin, N.W., Iron and anemia in human biology: A review of mechanisms (2008) Heart Fail Rev, 13, pp. 393-404 | ||
| 504 | |a van Veldhuisen, D.J., Anker, S.D., Ponikowski, P., Macdougall, I.C., Anemia and iron deficiency in heart failure: Mechanisms and therapeutic approaches (2011) Nat Rev Cardiol, 8, pp. 485-493 | ||
| 504 | |a von Haehling, S., Anker, M.S., Jankowska, E.A., Ponikowski, P., Anker, S.D., Anemia in chronic heart failure: Can we treat? What to treat? (2012) Heart Fail Rev, 17, pp. 203-210 | ||
| 504 | |a Jankowska, E.A., Malyszko, J., Ardehali, H., Koc-Zorawska, E., Banasiak, W., von Haehling, S., Macdougall, I.C., Ponikowski, P., Iron status in patients with chronic heart failure (2013) Eur Heart J, 34, pp. 827-834 | ||
| 504 | |a Silverberg, D.S., Wexler, D., Sheps, D., Blum, M., Keren, G., Baruch, R., Schwartz, D., Iaina, A., The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study (2001) J Am Coll Cardiol, 37, pp. 1775-1780 | ||
| 504 | |a Sharma, K.K., Improving bioavaibility of iron in Indian diets through food-based approaches for the control of iron deficiency anemia (2003) Revista Alimentación, Nutrición y Agricultura, 32, pp. 51-61 | ||
| 504 | |a Comín-Colet, J., Ruiz, S., Cladellas, M., Rizzo, M., Torres, A., Bruguera, J., A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: Influence on neurohormonal activation and clinical outcomes (2009) J Card Fail, 15, pp. 727-735 | ||
| 504 | |a González-Costello, J., Comín-Colet, J., Iron deficiency and anaemia in heart failure: Understanding the FAIR-HF trial (2010) Eur J Heart Fail, 12, pp. 1159-1162 | ||
| 504 | |a van der Meer, P., Groenveld, H.F., Januzzi Jr, J.L., van Veldhuisen, D.J., Erythropoietin treatment in patients with chronic heart failure: A meta-analysis (2009) Heart, 95, pp. 1309-1314 | ||
| 504 | |a Jin, B., Luo, X., Lin, H., Li, J., Shi, H., A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure (2010) Eur J Heart Fail, 12, pp. 249-253 | ||
| 504 | |a van Veldhuisen, D.J., Dickstein, K., Cohen-Solal, A., Lok, D.J., Wasserman, S.M., Baker, N., Rosser, D., Ponikowski, P., Randomized, double-blind, placebo controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia (2007) Eur Heart J, 28, pp. 2208-2216 | ||
| 504 | |a Ghali, J.K., Anand, I.S., Abraham, W.T., Fonarow, G.C., Greenberg, B., Krum, H., Massie, B.M., Armstrong, P., Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia (2008) Circulation, 117, pp. 526-535 | ||
| 504 | |a Desai, A., Lewis, E., Solomon, S., McMurray, J.J., Pfeffer, M., Impact of erythropoiesis stimulating agents on morbidity and mortality in patients with heart failure: An updated, post-TREAT metaanalysis (2010) Eur J Heart Fail, 12, pp. 936-942 | ||
| 504 | |a McMurray, J.J., Anand, I.S., Diaz, R., Maggioni, A.P., O’Connor, C., Pfeffer, M.A., Polu, K.R., Young, J.B., Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): A Phase III, anaemia correction, morbiditymortality trial (2009) Eur J Heart Fail, 11, pp. 795-801 | ||
| 504 | |a Swedberg, K., Young, J.B., Anand, I.S., Treatment of Anemia with Darbopoetin Alfa in Systolic Heart Failure (2013) N Engl J Med, 368, pp. 1210-1219 | ||
| 504 | |a Bolger, A.P., Bartlett, F.R., Penston, H.S., O’Leary, J., Pollock, N., Kaprielian, R., Chapman, C.M., Intravenous iron alone for the treatment of anemia in patients with chronic heart failure (2006) J Am Coll Cardiol, 48, pp. 1225-1227 | ||
| 504 | |a Toblli, J.E., Lombrana, A., Duarte, P., Di Gennaro, F., Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency (2007) J Am Coll Cardiol, 50, pp. 1657-1665 | ||
| 504 | |a Okonko, D.O., Grzeslo, A., Witkowski, T., Mandal, A.K., Slater, R.M., Roughton, M., Foldes, G., Ponikowski, P., Effect of intravenous iron sucrose on exercise tolerance in anemic and non-anemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial (2008) J Am Coll Cardiol, 51, pp. 103-112 | ||
| 504 | |a Anker, S.D., Comín Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Luscher, T.F., Ponikowski, P., Ferric carboxymaltose in patients with heart failure and iron deficiency (2009) N Engl J Med, 361, pp. 2436-2448 | ||
| 504 | |a Usmanov, R.I., Zueva, E.B., Silverberg, D.S., Shaked, M., Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency (2008) J Nephrol, 21, pp. 236-242 | ||
| 504 | |a Beard, J.L., Iron biology in immune function, muscle metabolism and neuronal functioning (2001) J Nutr, 131 (2 S-2), pp. 568-579 | ||
| 504 | |a Klip, I.T., Comín-Colet, J., Voors, A.A., Ponikowski, P., Enjuanes, C., Banasiak, W., Lok, D.J., Jankowska, E.A., Iron deficiency in chronic heart failure: An international pooled analysis (2013) Am Heart J, 165, pp. 575-582 | ||
| 504 | |a Jankowska, E.A., Rozentryt, P., Witkowska, A., Nowak, J., Hartmann, O., Ponikowska, B., Borodulin-Nadzieja, L., Ponikowski, P., Iron deficiency: An ominous sign in patients with systolic chronic heart failure (2010) Eur Heart J, 31, pp. 1872-1880 | ||
| 504 | |a Parikh, A., Natarajan, S., Lipsitz, S.R., Katz, S.D., Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: Prevalence and associations with anemia and inflammation (2011) Circ Heart Fail, 4, pp. 599-606 | ||
| 504 | |a Jankowska, E.A., von Haehling, S., Anker, S.D., Macdougall, I.C., Ponikowski, P., Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives (2013) Eur Heart J, 34, pp. 816-829 | ||
| 504 | |a Pfister, O., Evequoz, D., Mach, F., Moschovitis, G., Samiie, K., Waeber, G., Should anaemia and iron deficiency be treated in patients with chronic heart failure? (2012) Cardiovasc Med, 15, pp. 109-115 | ||
| 504 | |a Schena, F.P., Management of patients with chronic kidney disease (2011) Intern Emerg Med, 6, pp. 77-83 | ||
| 504 | |a Sica, D.A., Pharmacotherapy in congestive heart failure: Drug absorption in the management of congestive heart failure: Loop diuretics (2003) Congest Heart Fail, 9, pp. 287-292 | ||
| 504 | |a Ather, S., Chan, W., Bozkurt, B., Aguilar, D., Ramasubbu, K., Zachariah, A.A., Wehrens, X.H., Deswal, A., Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction (2012) J Am Coll Cardiol, 59, pp. 998-1005 | ||
| 504 | |a Okonko, D.O., Anker, S.D., Anemia in chronic heart failure: Pathogenetic mechanisms (2004) J Card Fail, 10 (1), pp. S5-S9 | ||
| 504 | |a Scharf, R.E., Management of bleeding in patients using antithrombotic agents: Prediction, prevention, protection and problem-oriented intervention (2009) Hamostaseologie, 29, pp. 388-398 | ||
| 504 | |a Nanas, J.N., Matsouka, C., Karageorgopoulos, D., Leonti, A., Tsolakis, E., Drakos, S.G., Tsagalou, E.P., Anastasiou-Nana, M.I., Etiology of anemia in patients with advanced heart failure (2006) J Am Coll Cardiol, 48, pp. 2485-2489 | ||
| 504 | |a Ponikowski, P., van Veldhuisen, D.J., Comin-Colet, J., Ertl, G., Komajda, M., Mareev, V., McDonagh, T., Anker, S.D., Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency (2015) Eur Heart J, 36, pp. 657-668. , for the CONFIRM-HF Investigators | ||
| 504 | |a McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., Falk, V., Ponikowski, P., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC (2012) Eur J Heart Fail, 14, pp. 803-869 | ||
| 504 | |a Jankowska, E.A., Kasztura, M., Sokolski, M., Bronisz, M., Nawrocka, S., Oleskowska-Florek, W., Zymlinski, R., Ponikowski, P., Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure (2014) Eur Heart J, 35, pp. 2468-2476 | ||
| 504 | |a Comín-Colet, J., Enjuanes, C., Gonzalez, G., Torrens, A., Cladellas, M., Merono, O., Ribas, N., Bruguera, J., Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status (2013) Eur J Heart Fail, 15, pp. 1164-1172 | ||
| 504 | |a Ezekowitz, J.A., McAlister, F.A., Armstrong, F.W., Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure (2003) Circulation, 107, pp. 223-225 | ||
| 504 | |a Arora, N.P., Ghali, J.K., Iron deficiency anemia in heart failure (2012) Heart Fail Rev, 18, pp. 485-501 | ||
| 504 | |a Maeder, M.T., Khammy, O., dos Remedios, C., Kaye, D.M., Myocardial and systemic iron depletion in heart failure: Implications for anemia accompanying heart failure (2011) J Am Coll Cardiol, 58, pp. 474-480 | ||
| 504 | |a Aung, N., Ling, H.Z., Cheng, A.S., Aggarwal, S., Flint, J., Mendonca, M., Rashid, M., Okonko, D.O., Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure (2013) Int J Cardiol, 168, pp. 1997-2002 | ||
| 504 | |a Okonko, D.O., Mandal, A.K., Missouris, C.G., Poole-Wilson, P.A., Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival (2011) J Am Coll Cardiol, 58, pp. 1241-1251 | ||
| 504 | |a Jankowska, E.A., Rozentryt, P., Witkowska, A., Nowak, J., Hartmann, O., Ponikowska, B., Borodulin-Nadzieja, L., Ponikowski, P., Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure (2011) J Cardiac Fail, 17, pp. 899-906 | ||
| 504 | |a Kasner, M., Aleksandrov, A.S., Westermann, D., Lassner, D., Gross, M., von Haehling, S., Anker, S.D., Tschope, C., Functional iron deficiency and diastolic function in heart failure with preserved left ejection fraction (2013) Int J Cardiol, 168, pp. 4652-4657 | ||
| 504 | |a van der Putten, K., Jie, K.E., van den Broek, D., Kraaijenhagen, R.J., Laarakkers, C., Swinkels, D.W., Braam, B., Gaillard, C.A., Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/ chronic heart failure patients (2010) Eur J Heart Fail, 12, pp. 943-950 | ||
| 504 | |a Haas, J.D., Brownlie, T., Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship (2001) J Nutr, 131, pp. 676-690 | ||
| 504 | |a Willis, W.T., Gohil, K., Brooks, G.A., Dallman, P.R., Iron deficiency: Improved exercise performance within 15 h of iron treatment in rats (1990) J Nutr, 120, pp. 909-916 | ||
| 504 | |a Finch, C.A., Miller, L.R., Inamdar, A.R., Person, R., Seiler, K., Mackler, B., Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction (1976) J Clin Invest, 58, pp. 447-453 | ||
| 504 | |a Guzman Mentesana, G., Baez, A.L., Lo Presti, M.S., Dominguez, R., Cordoba, R., Bazan, C., Strauss, M., Paglini-Oliva, P., Functional and structural alterations of cardiac and skeletal muscle mitochondria in heart failure patients (2014) Arch Med Res, 45, pp. 237-246 | ||
| 504 | |a Bayeva, M., Gheorghiade, M., Ardehali, H., Mitochondria as a therapeutic target in heart failure (2013) J Am Coll Cardiol, 61, pp. 599-610 | ||
| 504 | |a Yeo, J.T., Yeo, P.S., Ching-Chiew Wong, R., Ong, H.Y., Leong, K.T., Jaufeerally, F., Sim, D., Lam, C.S., Iron deficiency in a multi-ethnic Asian population with and without heart failure: Prevalence, clinical correlates, functional significance and prognosis (2014) Eur J Heart Fail, 16, pp. 1125-1132 | ||
| 504 | |a Macdougall, A.C., Strategies for iron supplementation: Oral versus intravenous (1999) Kidney Int, 55, pp. S61-S66 | ||
| 504 | |a Anker, S.D., von Haehling, S., (2012) Iron Deficiency and Anemia in Heart Failure, , 2nd ed. Bremen, Germany: UNI-MED Verlag | ||
| 504 | |a Crichton, R.R., Danielson, B.G., Geisser, P., (2008) Iron Therapy with Special Emphasis on Intravenous Administration, , 4th ed. Bremen, Germany: UNI-MED Verlag AG | ||
| 504 | |a Toblli, J.E., Cao, G., Olivieri, L., Angerosa, M., Comparative study of gastrointestinal tract and liver toxicity of ferrous sulfate, iron amino chelate and iron polymaltose complex in normal rats (2008) Pharmacology, 82, pp. 127-137 | ||
| 504 | |a Reinisch, W., Staun, M., Bhandari, S., Munoz, M., State of the iron: How to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease (2013) J Crohns Colitis, 7, pp. 429-440 | ||
| 504 | |a Britton, R.S., Ramm, G.A., Olynyk, J., Singh, R., O’Neill, R., Bacon, B.R., Pathophysiology of iron toxicity (1994) Adv Exp Med Biol, 356, pp. 239-253 | ||
| 504 | |a Geisser, P., Burckhardt, S., The pharmacokinetics and pharmacodynamics of iron preparations (2011) Pharmaceutics, 3, pp. 12-33 | ||
| 504 | |a Erichsen, K., Ulvik, R.J., Grimstad, T., Berstad, A., Berge, R.K., Hausken, T., Effects of ferrous sulphate and non-ionic ironpolymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease (2005) Aliment Pharmacol Ther, 22, pp. 831-838 | ||
| 504 | |a Mor, C., Fedele, F., Vasko, P., Frick, M., Mitchell, D., Diagnosis and treatment of iron deficiency and anemia in chronic heart failure: Current practice in four European countries (2011) Circulation, 124, p. 14991 | ||
| 504 | |a Sandek, A., Doehner, W., Anker, S.D., von Haehling, S., Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure (2012) Int J Cardiol, 157, pp. 80-85 | ||
| 504 | |a Sandek, A., Bauditz, J., Swidsinski, A., Buhner, S., Weber-Eibel, J., von Haehling, S., Schroedl, W., Anker, S.D., Altered intestinal function in patients with chronic heart failure (2007) J Am Coll Cardiol, 50, pp. 1561-1569 | ||
| 504 | |a Sandek, A., Swidsinski, A., Schroedl, W., Watson, A., Valentova, M., Herrmann, R., Scherbakov, N., Bauditz, J., Intestinal blood flow in patients with chronic heart failure. A link with bacterial growth, gastrointestinal symptoms, and cachexia (2014) J Am Coll Cardiol, 64, pp. 1092-1102 | ||
| 504 | |a Darshan, D., Frazer, D.M., Anderson, G.J., Molecular basis of ironloading disorders (2010) Expert Rev Mol Med, 12, p. 36 | ||
| 504 | |a Aapro, M., Osterborg, A., Gascon, P., Ludwig, H., Beguin, Y., Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron (2012) Ann Oncol, 23, pp. 1954-1962 | ||
| 504 | |a Camaschella, C., Silvestri, L., New and old players in the hepcidin pathway (2008) Haematologica, 93, pp. 1441-1444 | ||
| 504 | |a Auerbach, M., Clinical experience with intravenous iron (2007) Transfus Altern Transfus Med, 9, pp. 26-30 | ||
| 504 | |a Geisser, P., Baer, M., Schaub, E., Structure/histoxicity relationship of parenteral iron preparations (1992) Arzneimittelforschung, 42, pp. 1439-1452 | ||
| 504 | |a Toblli, J.E., Cao, G., Oliveri, L., Angerosa, M., Assessment of the oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model (2011) Arzneimittelforschung, 61, pp. 399-410 | ||
| 504 | |a Toblli, J.E., Cao, G., Oliveri, L., Angerosa, M., Evaluation of toxicity and oxidative stress induced by intravenous isomaltoside 1000 in a nonclinical model (2011) Arzneimittelforschung, 61, pp. 553-565 | ||
| 504 | |a Toblli, J.E., Cao, G., Olivieri, L., Angerosa, M., Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds (2010) Nephrol Dial Transplant, 25, pp. 3631-3640 | ||
| 504 | |a Van Wyck, D., Anderson, J., Johnson, K., Labile iron in parenteral iron formulations: A quantitative and comparative study (2004) Nephrol Dial Transplant, 19, pp. 561-565 | ||
| 504 | |a Silverstein, S.B., Gilreath, J.A., Rodgers, G.M., Intravenous iron therapy: A summary of treatment options and review of guidelines (2008) J Pharm Pract, 21, pp. 431-443 | ||
| 504 | |a Bailie, G.R., Comparison of rates of reported adverse events associated with i.v. iron products in the United States (2012) Am J Health Syst Pharm, 69, pp. 310-320 | ||
| 504 | |a Hayat, A., Safety issues with intravenous iron products in the management of anemia in chronic kidney disease (2008) Clin Med Res, 6, pp. 93-102 | ||
| 504 | |a KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. 3.2. Using iron agents (2006) Am J Kidney Dis, 47, pp. S58-S70 | ||
| 504 | |a Beard, J.L., Iron biology in immune function, muscle metabolism and neuronal functioning (2001) J Nutr, 131, pp. 568-580 | ||
| 504 | |a Ishida, J.H., Johansen, K.L., Iron and infection in hemodialysis patients (2014) Semin Dial, 27, pp. 26-36 | ||
| 504 | |a Clinical Practice Guideline for Anemia in Chronic Kidney Disease (2012) Kidney Int Suppl, 4, pp. 279-335 | ||
| 504 | |a Silverberg, S.D., Schwartz, D., Schwartz, I., Ben, A.E., The missed opportunities to diagnose and treat iron deficiency in patients hospitalized with heart failure (2013) Int J Cardiol, 168, pp. 2164-2166 | ||
| 504 | |a Ferinject, R., Summary of Product Characteristics, , Vifor International Inc., St Gallen, Switzerland | ||
| 504 | |a Filippatos, G., Farmakis, D., Colet, J.C., Dickstein, K., Luscher, T.F., Willenheimer, R., Parissis, J., Anker, S.D., Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: A subanalysis of the FAIR-HF trial (2013) Eur J Heart Fail, 15, pp. 1267-1276 | ||
| 504 | |a Jacobs, P., Johnson, G., Wood, L., Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose (1984) J Med, 15, pp. 367-377 | ||
| 504 | |a Nielsen, P., Kongi, R., Buggisch, P., Fischer, R., Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate (2005) Arzneimittelforschung, 55, pp. 376-381 | ||
| 504 | |a Sandek, A., Doehner, W., Anker, S.D., von Haehling, S., Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure (2012) Int J Cardiol, 157, pp. 80-85 | ||
| 504 | |a Palazzuoli, A., Silverberg, D., Iovine, F., Capobianco, S., Giannotti, G., Calabro, A., Campagna, S.M., Nuti, R., Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia (2006) Am Heart J, 152. , 1096.e9-e15 | ||
| 504 | |a Kourea, K., Parissis, J.T., Farmakis, D., Paraskevaidis, I., Panou, F., Filippatos, G., Kremastinos, D.T., Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure (2008) Eur J Cardiovasc Prevent Rehab, 15, pp. 365-369 | ||
| 504 | |a Lewis, G.D., Semigran, M.J., Givertz, M.M., Malhotra, R., Anstrom, K.J., Hernandez, A.F., Shah, M.R., Braunwald, E., Oral iron therapy for heart failure with reduced ejection fraction: Design and rationale for oral iron repletion effects on oxygen uptake in heart failure (2016) Circ Heart Fail, 9 | ||
| 504 | |a Gaber, R., Kotb, N.A., Ghazy, M., Nagy, H.M., Salama, M., Elhendy, A., Tissue Doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy (2012) Echocardiography, 29, pp. 13-18 | ||
| 504 | |a Toblli, J.E., Di Gennaro, F.P., Hospitalization and mortality in elderly cardio-renal patients with iron deficiency anemia receiving intravenous iron therapy: A five year follow-up from a pilot study (2012) Circulation, 126 | ||
| 504 | |a Gutzwiller, F.S., Schwenkglenks, M., Blank, P.R., Braunhofer, P.G., Mori, C., Szucs, T.D., Ponikowski, P., Anker, S.D., Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: An analysis for the UK (2012) Eur J Heart Fail, 14, pp. 782-790 | ||
| 504 | |a Rohde, L.E., Bertoldi, E.G., Goldraich, L., Polanczyk, C.A., Costeffectiveness of heart failure therapies (2013) Nat Rev Cardiol, 10, pp. 338-354 | ||
| 504 | |a Ponikowski, P., van Veldhuisen, D., Comin-Colet, J., Ertl, G., Komajda, M., Mareev, V., McDonagh, T., Anker, S.D., Rationale and design of the CONFIRM-HF study: A doubleblind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency (2014) ESC Heart Failure, 1, pp. 52-58. , for the CONFIRM-HF Investigators | ||
| 504 | |a Vullaganti, S., Goldsmith, J., Teruya, S., Alvarez, J., Helmke, S., Maurer, M.S., Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction (2014) J Geriatr Cardiol, 11, pp. 100-105 | ||
| 504 | |a Maurer, M.S., Teruya, S., Chakraborty, B., Helmke, S., Mancini, D., Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: Single-blind randomized clinical trial of safety and efficacy (2013) Circ Heart Fail, 6, pp. 254-263 | ||
| 504 | |a Avni, T., Leibovici, L., Gafter-Gvili, A., Iron supplementation for the treatment of chronic heart failure and iron deficiency: Systematic review and meta-analysis (2012) Eur J Heart Fail, 14, pp. 423-429 | ||
| 504 | |a Kapoor, M., Schleinitz, M.D., Gemignani, A., Wu, W.C., Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: A meta-analysis (2013) Cardiovasc Hematol Disord Drug Targets, 13, pp. 35-44 | ||
| 504 | |a McDonagh, T., Macdougall, I.C., Iron therapy for the treatment of iron deficiency in chronic heart failure: Intravenous or oral? (2015) Eur J Heart Fail, 17, pp. 248-262 | ||
| 504 | |a Beck-da-Silva, L., Piardi, D., Soder, S., Rohde, L.E., Pereira-Barretto, A.C., de Albuquerque, D., Bocchi, E., Clausell, N., IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia (2013) Int J Cardiol, 168, pp. 3439-3442 | ||
| 504 | |a Albaramki, J., Hodson, E.M., Craig, J.C., Webster, A.C., Parenteral versus oral iron therapy for adults and children with chronic kidney disease (2012) Cochrane Database Syst Rev, 1. , CD007857 | ||
| 504 | |a Provenzano, R., Schiller, B., Rao, M., Coyne, D., Brenner, L., Pereira, B.J., Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients (2009) Clin J Am Soc Nephrol, 4, pp. 386-393 | ||
| 504 | |a Spinowitz, B.S., Kausz, A.T., Baptista, J., Noble, S.D., Sothinathan, R., Bernardo, M.V., Brenner, L., Pereira, B.J., Ferumoxytol for treating iron deficiency anemia in CKD (2008) J Am Soc Nephrol, 19, pp. 1599-1605 | ||
| 504 | |a Qunibi, W.Y., Martinez, C., Smith, M., Benjamin, J., Mangione, A., Roger, S.D., A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients (2011) Nephrol Dial Transplant, 26, pp. 1599-1607 | ||
| 504 | |a Macdougall, I.C., Bock, A.H., Carrera, F., Eckardt, K.-U., Gaillard, C., Van Wyck, D., Roubert, B., Roger, S.D., FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia (2014) Nephrol Dial Transplant, 29, pp. 2075-2084 | ||
| 504 | |a Khalafallah, A.A., Dennis, A.E., Iron deficiency anaemia in pregnancy and postpartum: Pathophysiology and effect of oral versus intravenous iron therapy (2012) J Pregnancy, 2012, p. 630519 | ||
| 504 | |a Gafter-Gvili, A., Rozen-Zvi, B., Vidal, L., Leibovici, L., Vansteenkiste, J., Gafter, U., Shpilberg, O., Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia-systematic review and meta-analysis of randomized controlled trials (2013) Acta Oncol, 52, pp. 18-29 | ||
| 504 | |a Gasche, C., Berstad, A., Befrits, R., Beglinger, C., Dignass, A., Erichsen, K., Gomollon, F., Van Assche, G., Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases (2007) Inflamm Bowel Dis, 13, pp. 1545-1553 | ||
| 504 | |a Reinisch, W., Staun, M., Tandon, R.K., Altorjay, I., Thillainayagam, A.V., Gratzer, C., Nijhawan, S., Thomsen, L.L., A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED) (2013) Am J Gastroenterol, 108, pp. 1877-1888 | ||
| 504 | |a Kulnigg, S., Stoinov, S., Simanenkov, V., Dudar, L.V., Karnafel, W., Garcia, L.C., Sambuelli, A.M., Gasche, C., A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECTR) randomized controlled trial (2008) Am J Gastroenterol, 103, pp. 1182-1192 | ||
| 504 | |a Van Wyck, D.B., Mangione, A., Morrison, J., Hadley, P.E., Jehle, J.A., Goodnough, L.T., Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial (2009) Transfusion, 49, pp. 19-28. , for the Ferric Carboxymaltose Study Group | ||
| 504 | |a Van Wyck, D.B., Martens, M.G., Seid, M.H., Baker, J.B., Mangione, A., Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia (2007) Obstet Gynecol, 110, pp. 267-278 | ||
| 504 | |a Breymann, C., Gliga, F., Bejenariu, C., Strizhova, N., Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia (2008) Int J Gynecol Obstet, 101, pp. 67-73 | ||
| 504 | |a Seid, M.H., Derman, R.J., Baker, J.B., Banach, W., Goldberg, C., Rogers, R., Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial (2008) Am J Obstet Gynecol, 199, pp. e1-e7 | ||
| 504 | |a von Haehling, S., Jankowska, E.A., van Veldhuisen, D.J., Ponikowski, P., Anker, S.D., Iron deficiency and cardiovascular disease (2015) Nat Rev Cardiol, 12 (11), pp. 659-669 | ||
| 504 | |a Ebner, N., von Haehling, S., Iron and Exercise in Heart Failure: How to Assess Relevant Changes? (2016) Rev Esp Cardiol, 69 (3), pp. 237-238 | ||
| 504 | |a Enjuanes, C., Bruguera, J., Grau, M., Cladellas, M., González, G., Meroño, O., Estado del hierro en la insuficiencia cardíaca crónica: Impacto en síntomas, clase funcional y capacidad de ejercicio submáxima (2016) Rev Esp Cardiol, 69 (3), pp. 247-255 | ||
| 504 | |a Cohen-Solal, A., Damy, T., Terbah, M., Kerebel, S., Baguet, J.P., Hanon, O., High prevalence of iron deficiency in patients with acute decompensated heart failure (2014) Eur J Heart Fail, 16, pp. 984-991 | ||
| 520 | 3 | |a Iron is a micronutrient essential for cellular energy and metabolism, necessary for maintaining body homoeostasis. Iron deficiency (ID) is an important co-morbidity in patients with heart failure (HF). A major factor in the pathogenesis of anaemia, it is also a separate condition with serious clinical consequences (e.g. impaired exercise capacity) and poor prognosis in HF patients. ID affects up to 50% of HF patients, being particularly common in the elderly and patients with certain chronic diseases. The prevalence of iron deficiency is higher in the more advanced stages of HF, in women, in patients with elevated levels of inflammatory markers (e.g. C-reactive protein) as well as increased NT-proBNP. But even in low-risk patients such as NYHA I-II the prevalence remains at over 30%. ID is associated with a poor quality of life, impaired exercise tolerance, and mortality independent of haematopoietic effects in this patient population. International Guidelines recommend a diagnostic work-up for iron deficiency in patients with suspected HF. Data indicate that ID has detrimental effects in patients with coronary artery disease, HF, and pulmonary hypertension, and possibly in patients undergoing cardiac surgery. Iron absorption from oral iron preparations is generally poor, with slow and often inefficient iron repletion; moreover, up to 60% of patients experience gastrointestinal side effects. These problems may be exacerbated in HF due to decreased gastrointestinal absorption and poor compliance due to pill burden. Evidence for clinical benefits using oral iron is lacking. Intravenous (IV) iron administration has been shown to improve exercise capacity, symptom severity, and quality of life. Evidence suggests that these improvements occur independently of the presence of anemia. Similar findings were observed in patients with systolic HF and impaired ejection fraction in the double-blind, placebo-controlled FAIR-HF and CONFIRM-HF trials. IV iron therapy may be better tolerated than oral iron, although confirmation in longer clinical trials is awaited. Routine diagnosis and management of ID in patients with symptomatic HF regardless of anaemia status is advisable, and, based on current evidence, prompt intervention using IV iron therapy should now be considered, while still having into account that excess iron can be detrimental in cardiovascular disease. This update will review the iron metabolism in the context of anemia and HF; as well as the importance of early diagnosis and treatment of ID with IV iron in patients with HF. © 2016 Silver House. |l eng | |
| 593 | |a The American Heart Association, The American Stroke Association, Council on High Blood Pressure Research (AHA), Ciudad Autónoma de Buenos Aires, Argentina | ||
| 593 | |a División Cardiología, Pabellón Inchauspe, Hospital General de Agudos "Dr. J. M. Ramos Mejía", GCBA, Ciudad Autónoma de Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a ANEMIA |
| 690 | 1 | 0 | |a HEART FAILURE |
| 690 | 1 | 0 | |a HEPCIDIN |
| 690 | 1 | 0 | |a INTRAVENOUS |
| 690 | 1 | 0 | |a IRON |
| 690 | 1 | 0 | |a IRON DEFICIENCY |
| 690 | 1 | 0 | |a IRON THERAPY |
| 690 | 1 | 0 | |a ORAL |
| 690 | 1 | 0 | |a QUALITY OF LIFE |
| 700 | 1 | |a Bevacqua, R.J. | |
| 773 | 0 | |d Silver Horse SRL, 2016 |g v. 11 |h pp. 78-97 |k n. 2 |p Insuficiencia Cardiaca |x 18501044 |w (AR-BaUEN)CENRE-8510 |t Insuficiencia Cardiaca | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978661449&partnerID=40&md5=1e5ff0fa5e3ef933ea1a6bd019bc6d02 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_18501044_v11_n2_p78_Perel |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_18501044_v11_n2_p78_Perel |y Registro en la Biblioteca Digital |
| 961 | |a paper_18501044_v11_n2_p78_Perel |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 85527 | ||